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Abstract
Background: To determine the optimal approach to delineating patient-specific internal gross
target volumes (IGTV) from four-dimensional (4-D) computed tomography (CT) image data sets
used in the planning of radiation treatment for lung cancers.
Methods: We analyzed 4D-CT image data sets of 27 consecutive patients with non-small-cell lung
cancer (stage I: 17, stage III: 10). The IGTV, defined to be the envelope of respiratory motion of
the gross tumor volume in each 4D-CT data set was delineated manually using four techniques: (1)
combining the gross tumor volume (GTV) contours from ten respiratory phases (IGTVAllPhases); (2)
combining the GTV contours from two extreme respiratory phases (0% and 50%) (IGTV2Phases); (3)
defining the GTV contour using the maximum intensity projection (MIP) (IGTVMIP); and (4) defining
the GTV contour using the MIP with modification based on visual verification of contours in
individual respiratory phase (IGTVMIP-Modified). Using the IGTVAllPhases as the optimum IGTV, we
compared volumes, matching indices, and extent of target missing using the IGTVs based on the
other three approaches.
Results: The IGTVMIP and IGTV2Phases were significantly smaller than the IGTVAllPhases (p < 0.006 for
stage I and p < 0.002 for stage III). However, the values of the IGTVMIP-Modified were close to those
determined from IGTVAllPhases (p = 0.08). IGTVMIP-Modified also matched the best with IGTVAllPhases.
Conclusion: IGTVMIP and IGTV2Phases underestimate IGTVs. IGTVMIP-Modified is recommended to
improve IGTV delineation in lung cancer.
Background
Lung cancer remains the leading cause of cancer-related
mortality. Conventional photon radiotherapy for lung
cancer is associated with about 50% local tumor control
[1]. Missing the target as a result of tumor motion has
been considered one of the main reasons for local failure
[2]. Researchers have reported that ~40% of lung tumors
move > 5 mm and that 10–12% move > 1 cm [3,4]. Sev-
eral strategies have recently been developed to address the
issue of tumor motion and improve local control [2]. For
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example, the development of image-guided radiotherapy
(IGRT) has allowed for more accurate tumor targeting, so
it is rapidly replacing conventional radiotherapy for lung
cancer [2]. In order to account for tumor motion, the
International Commission on Radiation Units and Meas-
urements (ICRU) report 62 introduced the concept of an
internal target volume (ITV), defined as the clinical target
volume (CTV) plus an additional margin to account for
geometric uncertainties due to internal variations in
tumor position, size, and shape. Using current imaging
techniques, the CTV cannot be visualized. Consequently,
generation of the ITV requires delineation of the gross
tumor volume (GTV) on each of the phases that constitute
the four-dimensional (4-D) computed tomography (CT)
image data set, followed by expansion of each GTV to
account for microscopic disease. The ITV is then deter-
mined to be the envelope of motion of the CTV. In order
to make the determination of the ITV more efficient, we
have proposed the concept of the internal gross tumor
volume (IGTV), which explicitly accounts for internal var-
iations in tumor position, size, and shape but can be
derived directly from imaging studies [2]. The ITV is then
determined to be the IGTV plus a margin that accounts for
microscopic disease.
Traditionally, the margin necessary to account for internal
motion of tumors in the thorax has been determined
using an isotropic expansion determined by population-
based estimates of respiratory motion. However, because
breathing characteristics vary greatly among individual
patients, such population-based estimates may overesti-
mate or underestimate the margin needed for a given
patient. Moreover, respiratory-induced tumor motion is
known not to be anisotropic; typical tumor paths are
those of elongated and possible curved ellipses. The
advent of the multislice helical CT scanner combined with
the establishment of temporal correlation between respi-
ratory motion and the CT acquisition process have
allowed tumor size, shape, and position to be observed at
multiple times during a patient's respiratory cycle [5,6].
The resultant CT data set, called the 4-D CT or respiration-
correlated CT data set, provides patient-specific informa-
tion about tumor position, shape, and size at different
phases of the respiratory cycle.
Although using 4-D CT data provides a reliable estimate
of the extent of tumor motion due to respiration in three
dimensions, its clinical implementation poses some chal-
lenges. Ideally, the IGTV should be determined by con-
touring the GTV on each of the ten phase image sets. The
combination of these individual three dimensional (3-D)
volumes into a single 3-D volume represents the IGTV,
which accounts for respiratory motion. However, con-
touring the tumor volume on ten different data sets for
each patient increases the workload compared with con-
touring in only one dataset. In these instances, post-
processing tools, such as the maximum intensity projec-
tion (MIP), have been shown to improve radiotherapy
planning efficiency [7]. The MIP of a 4D-CT data set
reduces the multiple 3-D CT data available from a 4-D CT
data set into a single 3-D CT data set, where each voxel in
the MIP represents the maximum intensity encountered
by corresponding voxels in all individual 3-D phase image
sets of the 4-D CT data set. The IGTV is then determined
based on the GTV delineation on the single 3-D CT data
set. Alternatively, some cancer centers have used breath-
hold spiral CT imaging to acquire images at the two
extremes of the respiratory cycle [2,7]; contouring the GTV
at these extremes (the end-expiration and the end-inspira-
tion phases) and then combining these two 3-D volumes
yields the IGTV. A limited number of studies have ana-
lyzed the accuracy of the MIP and two-phase IGTV delin-
eation techniques relative to full ten-phase method for
determining IGTV [8-11].
The aim of this study, therefore, was to evaluate the accu-
racy of 4-D CT MIP-based IGTV delineation and two-
phase-based IGTV delineation compared to ten-phase
IGTV delineation as a reference. We also examined the
accuracy of the MIP-based IGTV delineation after applying
a modification through visual verification of GTV cover-
age in individual respiratory phases.
Methods
Data acquisition
As a retrospective review of radiation treatment planning,
this study was included under an Institutional Review
Board-approved retrospective chart review protocol. We
studied 27 consecutive patients with non-small-lung can-
cer (NSCLC) who underwent 4-D CT simulation for treat-
ment planning and received definitive radiotherapy at our
institution between 2005 and 2006. Of these 27 patients,
17 had stage I disease and received stereotactic body radi-
otherapy (SBRT), and 10 had stage III disease and received
intensity-modulated radiotherapy (IMRT). 4-D CT image
data sets each consisting of 10 respiratory phases, were
acquired on a multislice CT scanner (Discovery ST, GE
Medical Systems, Madison, WI) by sorting CT images
based on the phase of an external respiratory monitor
(Real-time Position Management System; Varian Medical
Systems, Inc., Palo Alto, CA) [12]. MIPs of the 4D-CT data
sets were then generated from the individual phase images
as described elsewhere [5,6].
Patient-specific IGTV determination
We determined patient-specific IGTVs using the demon-
strable extent of tumor motion shown in the 4-D CT
images. We used four approaches to determine these
IGTVs: (1) contouring the GTV on each of the ten respira-
tory phases of the 4D-CT data set and combining theseRadiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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GTVs to produce IGTVAllPhases; (2) contouring the GTV on
the MIP of the 4-D CT data set to produce IGTVMIP; (3)
contouring the GTV on the extreme respiratory phases
(0% phase = peak inhalation, 50% phase = peak exhala-
tion) and combining these GTVs to produce IGTV2Phases;
and (4) contouring the GTV on the MIP of the 4-D CT data
set and then modifying these contours using visual verifi-
cation of coverage in each phase of the 4-D CT data set to
produce IGTVMIP-Modified. Visual verification of coverage in
each phase was achieved by overlaying the MIP based GTV
contour onto each phase of the 4-D CT data set. Thus,
each of these 3D volumes (IGTVAllPhases, IGTVMIP,
IGTV2Phases, and IGTVMIP-Modified) represented the demon-
strable respiratory tumor motion volumes, or IGTVs. Fig-
ures 1 and 2 show the results obtained using these
different approaches in the determination of IGTV for
cases of stage I and stage III disease, respectively. For con-
sistency in contouring, all GTV contours in each respira-
tory phase of the 4-D CT and MIP data sets were drawn by
a single radiation oncologist (ME) and verified by another
radiation oncologist (JYC). We used a lung window on the
CT data set to contour the primary tumor and a mediasti-
num window to contour any involved lymph nodes.
Diagnostic CT of chest with intravenous contrast and PET/
CT were used to guide our involved lymph nodes contour-
ing as described by our previous publication (2). A total
of 324 GTVs were delineated with 12 GTVs delineated for
each patient (GTV in each of 10 respiratory phases,
IGTVMIP, and IGTVMIP-Modified). For stage III disease,
involved hilar or mediastinal lymph nodes were con-
toured and analyzed independently.
Delineation of IGTV for stage I lung tumors based on (a) IGTVMIP, (b) IGTVMIP-Modified, (c) IGTV2Phases, and (d) IGTVAllPhases of a  4-D CT data set Figure 1
Delineation of IGTV for stage I lung tumors based on (a) IGTVMIP, (b) IGTVMIP-Modified, (c) IGTV2Phases, and (d) 
IGTVAllPhases of a 4-D CT data set. MIP-based contours, as shown in panels (a) and (b), are as they appear on the MIP data 
set. Phase-based contours, as shown in panels (c) and (d), are registered to the peak exhalation phase of the 4-D CT data set.Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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Data analysis
We evaluated the IGTVs determined using each of the
three contouring approaches against an all phases IGTV
determined by contouring all ten respiratory phases of the
4-D CT data set (IGTVAllPhases). Specifically, we compared
the following metrics for each 3D volume: matching
index, total GTV volume and under or over-estimated vol-
ume.
Matching index calculation
The matching index (MI) of any two 3D volumes A and B
is defined as the ratio of the intersection of A with B to the
union of A and B, that is,
As can be deduced from this equation, the maximum
value of the MI is 1 if the two volumes are identical, and
the minimum value is 0 if the volumes are completely
non-overlapping.
Volume difference calculation
While the matching index is a good measure of how well
the shape of any two volumes match each other, it cannot
discriminate between overestimation and underestima-
tion. To gain better insight into any over/underestimation
of the IGTV, we computed the differences in IGTV
between the all phases volume (IGTVAllPhases) and the
three test volumes (IGTVMIP, IGTV2Phases, and IGTVMIP-Mod-
ified). For each pair of volumes, we computed the underes-
timation and overestimation volumes (VUnder and VOver)
using the following equations:
MI
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=
∩
∪
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Delineation of IGTV for stage III lung tumors based on (a) IGTVMIP, (b) IGTVMIP-Modified, (c) IGTV2Phases, and (d) IGTVAllPhases of a  4-D CT data set Figure 2
Delineation of IGTV for stage III lung tumors based on (a) IGTVMIP, (b) IGTVMIP-Modified, (c) IGTV2Phases, and (d) 
IGTVAllPhases of a 4-D CT data set. MIP-based contours, as shown in panels (a) and (b), are as they appear on the MIP data 
set. Phase-based contours, as shown in panels (c) and (d), are registered to the peak exhalation phase of the 4D-CT data set.Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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where VAllPhases is the volume in ten respiratory phases, Vtest
is the test volume, and "\" denotes the set difference. The
underestimation and overestimation volumes were com-
puted as integrals over the z coordinate of the correspond-
ing transverse areas as follows:
where AAllPhases is the area in ten respiratory phases and
ATest is the test area. The underestimation area (AUnder) and
the overestimation area (AOver) defined as
were computed for each axial level by performing the
Delaunay triangulation for the union of the all phases and
test contour points and computing the areas as a sum of
the corresponding triangular areas (see Figure 3). Given a
set of data points in the plane, the Delaunay triangulation
is a set of triangles such that no data points are contained
in any triangle's circumscribed circle. Delaunay triangula-
tions maximize the minimum angle of all the triangles in
the triangulation and they tend to avoid skinny (or close-
to-degenerate) triangles. We used the Delaunay triangula-
tion implemented in a high-level graphical analysis and
programming package, MATLAB (The Mathworks, Inc.:
http://www.mathworks.com), which is based on the
Quickhull algorithm [13].
Statistical analysis
To estimate any statistically significant differences
between the IGTVs determined using each test volume
(IGTVMIP, IGTV2Phases, and IGTVMIP-Modified) and the IGTV
determined using the all phases volume (IGTVAllPhases), we
used a paired sample t-test in each case to determine p,
with p < 0.05 considered significant. All statistical analyses
were performed using the SPSS software package (v.10;
SPSS Inc., Chicago, IL).
Results
Table 1 shows the superior-inferior (SI) motion and the
IGTVs based on the test and all phases volumes for the
stage I lung tumors. SI motion ranged from 0 cm to 2.17
cm, with almost half (8/17) of the tumors exhibiting SI
motion > 1 cm. To study the influence of magnitude of SI
motion on the accuracy of IGTV delineation, we grouped
the 17 patients into two groups: those with tumor motion
> 1.00 cm and those with tumor motion ≤1.00 cm. In gen-
eral, we found that, regardless of the magnitude of SI
motion, the IGTVMIP and IGTV2Phases (mean ± SD: 14.14 ±
14.89 cm3 and 13.93 ± 15.69 cm3, respectively) were con-
sistently smaller than the IGTVAllPhases (mean ± SD: 16.60
± 17.05 cm3), whereas the IGTVMIP-Modified (mean ± SD:
16.33 ± 16.67 cm3) were similar to the reference IGTV. A
paired sample t-test revealed that the IGTVMIP  and
IGTV2Phases differed significantly from the IGTVAllPhases(p <
0.001), while the IGTVMIP-Modified did not differ signifi-
cantly from the reference IGTV (p = 0.08).
Table 2 shows the MI values for each of the three test
IGTVs. As shown, the IGTVMIP-Modified (mean ± SD: 0.90 ±
0.02) most closely matched the IGTVAllPhases, with
IGTV2Phases (mean ± SD: 0.81 ± 0.06) and IGTVMIP (mean
± SD: 0.80 ± 0.05) following. There were no significant
differences between IGTV2Phases and IGTVMIP (p = 0.728),
but the differences in MI between IGTVMIP and IGTVMIP-
Modified and those between IGTV2Phases IGTVMIP-Modified were
significant (p < 0.001, respectively)
We performed a comparative analysis of the MI values of
the two patient groups (patients with SI motion ≤1 cm
and those with SI motion > 1 cm) with stage I disease.
There was no strong correlation between the MI and the
magnitude of SI motion, although the MI of IGTV2Phases in
some patients with SI motion ≤1 cm was lower than the
general trend in patients with SI motion > 1 cm. Although
the magnitude of SI motion did not significantly impact
the accuracy of the IGTV contouring approaches, we
found that the location of the primary tumor impacted
IGTV contouring accuracy (Table 2). For example, we
found that tumors located near the diaphragm (cases 1, 2,
3, and 15), mediastinum (case 8), and chest wall (cases 4,
6, 9, 10, and 12) appeared to have worse MI values than
tumors located in the peripheral lung parenchyma (cases
5, 7, 11, 13, 14, 16, and 17) although it didn't reach sta-
tistical significance.
Table 3 shows the SI motion and the IGTVs based on the
test and all phases volumes for the 10 stage III lung
tumors. As shown, the majority of these tumors (9/10)
exhibited SI motion < 1 cm, so it was not meaningful to
group these patients according to the 1-cm-SI motion
threshold.
As with stage I lung tumors, we found that, regardless of
the magnitude of SI motion, the IGTVMIP and IGTV2Phases
(mean ± SD: 193.27 ± 135.09 cm3 and 194.81 ± 133.86
cm3, respectively) were consistently smaller than the
IGTVAllPhases (mean ± SD: 209.96 ± 139.95 cm3), whereas
the IGTVMIP-Modified(mean ± SD: 206.00 ± 137.34 cm3) was
similar to the all phases IGTV. A paired sample t-test
revealed that the IGTVMIP and IGTV2Phases differed signifi-
cantly from the IGTVAllPhases  (p  < 0.001), while the
IGTVMIP-Modified differed less (p = 0.01).
VA z A z d z
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Table 4 shows the MI values for each IGTV based on the
test volumes and on the all phases volume for patients
with stage III disease. In general, we found that the
GTVMIP-Modified-based IGTV (mean ± SD: 0.93 ± 0.20)
matched the GTVAllPhases-based IGTV the closest, followed
by the IGTVs based on GTV2Phases (mean ± SD: 0.91 ±
0.05) and GTVMIP (mean ± SD: 0.86± 0.07). There was a
significant difference between GTV2Phases-based and
GTVMIP-based IGTVs (p  = 0.05) and between GTVMIP-
based and GTVMIP-Modified-based IGTVs (p = 0.03).
The volumetric underestimation and overestimation
between the all phases volume and the test volumes for
patients with stage I and III disease are shown in Table 5.
For stage I disease, the maximum volumetric underesti-
mations for IGTVMIP, IGTV2Phases, and IGTVMIP-Modified
compared to IGTVAllPhases  were 30.86%, 21.2%, and
8.53%, respectively. For stage III disease, the maximum
volumetric underestimations for IGTVMIP, IGTV2Phases, and
IGTVMIP-Modified compared to IGTVAllPhases were 23.85%,
22.25%, and 6.66%, respectively. The average volumetric
underestimation was 17.3% for IGTVMIP, 19.3% for
IGTV2Phases, and 5.3% for IGTVMIP-Modified in stage I tumors
and 12.1% for IGTVMIP, 8.9% for IGTV2Phases, and 4.2% for
IGTVMIP-Modified in stage III tumors. In sum, we found that
the volumetric underestimation for IGTVMIP-Modified was
consistently lower than the underestimation for IGTVs
based on the other test volumes. We also observed that the
volumetric underestimation percentages in stage III dis-
ease were lower than those in stage I disease. However,
because GTVs are by definition larger in stage III than in
stage I disease, the absolute volume underestimation was
generally higher in stage III disease. Volumetric overesti-
mation occurred in both stage I and stage III disease for
both IGTVMIP  and IGTVMIP-Modified. Overestimation for
IGTVMIP-Modified was slightly higher than that for IGTVMIP,
but both percentages were lower than 5.0% for the aver-
age volume overestimation and 10.10% for the maximum
volume overestimation. Because IGTV2Phases is a subset of
IGTVAllPhases, the volumetric overestimation for IGTV2Phases
compared to the reference IGTV was always equal to zero.
Figure 4 illustrates the proportional volumetric underesti-
mations (Fig. 4a) and overestimations (Fig. 4b) in the 17
individual patients with stage I disease. We found that vol-
umetric underestimation was > 10% using either IGTVMIP
or IGTV2Phases in 15 patients, but in no patients when
IGTVMIP-Modified was used. Volumetric underestimation >
20% occurred in 5 patients using the IGTVMIP and in 7
patients using the IGTV2Phases. Of the 5 patients in whom
volumetric underestimation was > 20% using IGTVMIP, 2
had lesions near or attached to the diaphragm, 1 had a
lesion near or attached to the chest wall, and another had
a lesion near or attached to the mediastinum. Figure 5
illustrates the volumetric underestimations (Fig. 5a) and
overestimations (Fig. 5b) in the 10 patients with stage III
disease. We found that volumetric underestimation was >
5% in 9 patients using IGTVMIP, 8 patients using
IGTV2Phases, and 2 patients using IGTVMIP-Modified. Volu-
metric underestimation > 10% occurred in 6 patients
using IGTVMIP, 1 patient using IGTV2Phases, but no patients
using IGTVMIP-Modified. In general, we found that the lowest
volumetric underestimation was achieved consistently
using the modified MIP approach to delineate the IGTV.
To analyze the accuracy of these contouring approaches in
involved lymph nodes, we conducted the second analysis
of involved lymph nodes in above stage III disease. Our
data showed that IGTVMIP-Modified volume of lymph nodes
(mean ± SD: 32.95 ± 40.86 cm3) matched most closely
with IGTVAllPhases volumes of lymph nodes (mean ± SD:
34.26 ± 42.56 cm3, p = 0.24), while IGTV2Phases  and
IGTVMIP lymph node volumes (mean ± SD: 29.15 ± 38.14
and 25.63 ± 34.55 cm3 respectively) differed significantly
with IGTVAllPhases lymph node volume (p = 0.04 and 0.05
respectively, volume underestimation in all cases). In
addition, the match index of lymph node IGTVMIP-Modified
was not significantly different from IGTV2Phases (p = 0.14)
but was significantly different from IGTVMIP values (p =
Computation of the underestimation area (dark gray) and the  overestimation area (light gray) of the test area (area inside  the dashed line) compared with reference area (area inside  the solid line) Figure 3
Computation of the underestimation area (dark 
gray) and the overestimation area (light gray) of the 
test area (area inside the dashed line) compared with 
reference area (area inside the solid line). The areas 
were computed using the Delaunay triangulation which is 
shown in the regions of interest.Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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0.001 for both cases). IGTVMIP-Modified  and IGTV2Phases
matched better with IGTVAllPhases (match index mean ±
SD: 0.81 ± 0.08, range: 0.75–0.91 for IGTVMIP-Modified, and
0.77 ± 0.08, range: 0.65 to 0.88 for IGTV2Phases) compared
with IGTVMIP (mean ± SD: 0.62 ± 0.11; Range: 0.46 to
0.76).
Discussion
Real-time tumor motion tracking provides most compre-
hensive data for respiratory tumor motion management.
However, it is a challenging technique to implement in
the clinical setting and more research is needed to make
its clinical implementation more practical [14]. Although
both MIP-based and two-phase-based approaches have
been shown to more accurately delineate the GTV than
conventional 3D CT-based planning, their accuracy has
not been compared with that of ten-phase contouring
approach particularly in stage III disease. Jin et al, in a
phantom study, examined the feasibility of a method to
determine ITV based on motion information obtained
from select phases of a respiratory cycle [15]. They
reported that adequate estimation of IGTV could in gen-
eral be achieved by combining motion information from
the extremes of motion in most cases and in some cases by
the addition of motion information from an intermediate
phase. Underberg et al. [8] reported that MIP-based con-
touring could provide reliable margins for determining
the IGTV for stage I lung tumors treated with SBRT. How-
ever, their method did not include visual verification of
the MIP-defined GTV contour through each individual
phase of the 4D CT (IGTVMIP-Modified). Bradley et al. [9]
compared helical-, MIP-, and average-intensity (AI)-based
Table 1: SI motion and IGTVs based on the test volumes (IGTVMIP, IGTV2Phases, and IGTVMIP-Modified) and the reference volume 
(IGTVAllPhases) for stage I tumors
Patient No SI Motion (cm) IGTVMIP
(cm3)
IGTVMIP-Modified
(cm3)
IGTVAllPhases
(cm3)
IGTV2Phases
(cm3)
1 1.06 5.82 7.98 8.32 6.56
2 1.37 8.53 10.51 9.98 7.49
3 1.70 12.88 15.85 16.54 13.23
4 1.08 4.92 5.49 5.44 3.72
5 0.15 1.64 1.79 1.80 1.46
6 2.17 17.64 22.16 23.39 18.98
7 1.27 23.08 26.06 26.28 21.77
8 0.54 12.45 15.73 15.76 12.82
9 0.18 21.80 24.50 24.96 20.92
10 0.00 60.04 66.90 67.75 63.67
11 0.41 2.46 2.80 2.85 2.27
12 1.77 32.90 37.65 39.39 33.14
13 0.14 2.08 2.27 2.23 1.84
14 0.10 1.53 1.90 1.93 1.74
15 1.62 18.59 21.26 21.69 16.66
16 0.66 10.70 11.31 10.60 7.77
17 0.09 3.35 3.45 3.33 2.70Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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4-D CT imaging to find the optimal approach for deter-
mining the patient-specific IGTV for SBRT for stage I lung
cancer. They found that the MIP-defined GTV was signifi-
cantly larger than the helical-defined and average CT-
defined GTVs. However, in their study, Bradley et al. did
not compare the GTV based on GTVMIP with that based on
GTVAllPhases, the optimal reference volume. Bradley et al.
[9] did not discuss their results in the context of tumor
location in their study. In another study, Cai et al. [10]
determined the IGTVs for six lung tumors using a simula-
tion method based on dynamic magnetic resonance imag-
ing (dMRI) and MIPs. They found that MIP-based IGTVs
were smaller than dMRI-based IGTVs. They concluded
that because of the low temporal resolution and retrospec-
tive re-sorting, 4-D CT might not accurately depict the
excursion of a moving tumor. Recent data by Rietzel et al
also support our observation that tumor delineation on
the MIP with subsequent visual verification of contours
over all individual phases of the 4D CT yielded the best
estimate of IGTV. However, there the performance of this
approach in the delineation of involved lymph nodes was
not separately addressed [11]. In daily clinical practice,
tumor contouring in stage III disease is more challenging
than in stage I disease because of the larger tumor volume,
more complicated tumor shape, involvement of critical
structures, and potential involvement of multiple lymph
nodes in which tissue density is similar to that of the
tumor. In addition, although the two-phase-based
approach has been used to delineate IGTVs in the clinical
setting, there is scant data on the accuracy of such two-
phase-based IGTVs in either stage I or stage III disease
[16]. Our study showed that both MIP-based and two-
phase-based IGTVs underestimate the 10-phase-based
IGTV in both stage I and III disease including involved
lymph nodes, which can potentially result in marginal
under-dosing, and that the IGTVMIP-Modified consistently
Table 2: Matching index values for each IGTV based on IGTVMIP, IGTV2Phases, and IGTVMIP-Modified relative to the reference IGTVAllPhases 
in stage I disease
Patient No Location (Adjacent) IGTVMIP IGTV2Phases IGTVMIP-Modified
1 Diaphragm 0.69 0.79 0.88
2 Diaphragm 0.79 0.75 0.88
3 Diaphragm 0.77 0.80 0.92
4 Chest wall 0.82 0.68 0.90
5 Lung parenchyma 0.83 0.81 0.88
6 Chest wall 0.72 0.80 0.89
7 Lung parenchyma 0.84 0.83 0.91
8 Mediastinum 0.74 0.81 0.92
9 Chest wall 0.84 0.84 0.91
10 Chest wall 0.87 0.94 0.95
11 Lung parenchyma 0.79 0.80 0.90
12 Chest wall 0.83 0.84 0.93
13 Lung parenchyma 0.82 0.83 0.90
14 Lung parenchyma 0.75 0.90 0.91
15 Diaphragm 0.79 0.77 0.89
16 Lung parenchyma 0.85 0.73 0.88
17 Lung parenchyma 0.88 0.81 0.91Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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had the lowest percentages of volumetric underestima-
tion, which indicates that the IGTVMIP-Modified approach is
the most accurate in delineating the IGTV.
For the MIP-based approach, several potential sources of
uncertainty/error exist: (1) the MIP image may not fully
display mobile structures if the adjacent structures have
similar (or higher) densities, which is the case for lesions
located near the mediastinum, diaphragm, liver, or chest
wall; and (2) the physician may misinterpret the MIP
images because of tumor border smearing. (3) The tumor
spicula can not be visualized on the MIP projections due
to smearing of the tumor edge. Indeed, our data show that
the MI was poor and volumetric underestimation was
high using the MIP-based approach to delineate IGTVs in
most of lesions near the mediastinum, diaphragm, liver,
and chest wall. Of these lesions, those closer to the dia-
phragm and liver had the lowest MI values, which could
have been due to the significant motion of the diaphragm
and liver and the MIP image's inability to record differ-
ences between the lesion and the diaphragm and liver. We
are currently developing software that excludes dia-
phragm and liver images in some breathing phases using
cine CT images so that better tumor MIP images will be
preserved (data to be published). We should note that
MIP images do not reflect the densities of tumors, lungs,
and other normal tissues accurately enough for dose cal-
culation in treatment planning [17]. Thus, a free-breath-
ing CT image set, a 4-D scan of a single respiratory phase,
or an average CT image set extracted from a 4-D CT data
set should be used for treatment planning and dose calcu-
lation. This would be especially important in proton ther-
apy, which is more sensitive to tumor motion and changes
in tissue density. In a previous study on 4-D CT in proton
therapy planning, we found that a MIP density override
Table 3: SI motion and IGTVs based on the test volumes (IGTVMIP, IGTV2Phases, and IGTVMIP-Modified) and the reference volume 
(IGTVAllPhases) for stage III tumors
Patient No SI Motion (cm) IGTVMIP
(cm3)
IGTVMIP-Modified
(cm3)
IGTVAllPhases
(cm3)
IGTV2Phases
(cm3)
1 0.09 64.91 77.33 79.94 74.42
2 0.12 202.85 228.55 238.40 216.29
3 0.21 135.59 146.62 151.40 138.72
4 0.18 221.50 230.85 233.74 222.22
5 0.62 23.87 30.59 29.98 23.33
6 0.11 446.14 450.31 458.21 439.86
7 0.96 242.38 265.47 268.58 244.76
8 0.14 347.06 368.97 373.61 351.46
9 0.18 36.69 39.40 36.87 34.03
10 1.77 211.70 221.96 228.89 203.01
Table 4: Matching index values for each IGTV based on IGTVMIP, 
IGTV2Phases, and IGTVMIP-Modified relative to the reference 
IGTVAllPhases in stage III disease
Patient No GTVMIP GTV2Phases GTVMIP-Modified
1 0.76 0.93 0.92
2 0.83 0.91 0.92
3 0.88 0.92 0.94
4 0.92 0.95 0.95
5 0.74 0.78 0.90
6 0.95 0.96 0.95
7 0.87 0.91 0.94
8 0.90 0.94 0.94
9 0.87 0.92 0.91
10 0.86 0.89 0.90Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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for tumor contouring in an average CT data set was the
optimal approach [18].
For the two-phase-based approach, tumor deformation
between the two extreme phases of breathing and the
curved motion pathway during each breathing cycle may
introduce uncertainty. In most cases, however, we found
that the MI of the two-phase-based IGTV was slightly
higher than that of MIP-based IGTV, which indicates that
most tumors moved in a generally straightforward SI
direction and that tumor deformation during breathing
was minimal. Particularly in stage III disease, we found
that the volumetric underestimation was generally lower
for the two-phase-based IGTV than for the MIP-based
IGTV. Therefore, if 4-D CT based IGTVMIP-Modifiedis not
available, the two-phase-based IGTV is a reasonable alter-
native approach to take tumor motion into consideration
although it is not optimal one.
In clinical setting, it is common to prescribe the dose to
PTV which takes additionally clinical target volume (CTV)
and set-up uncertainty into consideration. The volume-
underestimation will be reduced if PTV was used to com-
pare above mentioned four approaches. We evaluated the
effect of this underestimation on the PTV in a case with
maximal underestimation of the IGTV in stage I disease.
IGTV was expanded by 1.6 cm (0.8 cm for CTV, 0.3 cm to
account for variability in the determination of motion
extent and 0.5 cm for image guided patient setup). Analy-
sis of volumetric underestimation of the PTV was carried
out in the same manner as described for IGTV. Our results
showed that the volume underestimation reduced from
30.86%, 21.2%,8.53% in IGTV to 13.3%, 5.18% and
3.36% in PTV for IGTVMIP, IGTV2Phases, IGTVMIP-Modified
respectively. In general, this improvement is more dra-
matic in the lesions with the smaller size such as stage I
disease. However, when ablative dose is attempted in clin-
ical setting but sparing critical structures is concerning
Table 5: Summary of the volumetric percentage underestimation and overestimation for each IGTV based on IGTVMIP, IGTV2Phases, 
and IGTVMIP-Modified relative to the reference IGTVAllPhases.
Underestimation (%) IGTVMIP IGTV2Phases IGTVMIP-Modified
Stage I patients
Avg. ± SD 17.33 ± 6.56 19.32 ± 5.93 5.36 ± 1.71
Range 6.32–30.86 6.03–31.76 2.30–8.53
Stage III patients
Avg. ± SD 12.11 ± 6.23 8.95 ± 5.15 4.21 ± 1.66
Range 4.04–23.85 4.01–22.25 1.20–6.66
Overestimation (%) IGTVMIP IGTV2Phases IGTVMIP-Modified
Stage I patients
Avg. ± SD 3.23 ± 2.35 0 4.80 ± 2.39
Range 0.34–8.64 0 1.30–10.07
Stage III patients
Avg. ± SD 2.36 ± 1.79 0 3.21 ± 2.22
Range 1.06–6.92 0 1.43–8.09
Average ± standard deviation and range are reported for stage I and stage III tumors.Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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Stage I tumors Figure 4
Stage I tumors. (a) Volumetric underestimation for each IGTV based on IGTVMIP, IGTV2Phases, and IGTVMIP-Modified relative to 
the reference IGTVAllPhases. (b) Volumetric overestimation for each IGTV based on IGTVMIP, IGTV2Phases, and IGTVMIP-Modified 
relative to the IGTVAllPhases. (Note: IGTV2Phases is a subset of IGTVAllPhases, hence the volumetric overestimation for IGTV2Phases 
is always equal to zero.)
a.
b.Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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Stage III tumors Figure 5
Stage III tumors. (a) Volumetric underestimation for each IGTV based on IGTVMIP, IGTV2Phases, and IGTVMIP-Modified relative 
to the IGTVAllPhases. (b) Volumetric overestimation for each IGTV based on IGTVMIP, IGTV2Phases, and IGTVMIP-Modified relative to 
the IGTVAllPhases. (Note: IGTV2Phases is a subset of IGTVAllPhases, hence the volumetric overestimation for IGTV2Phases is always 
equal to zero.)
a.
b.Radiation Oncology 2009, 4:4 http://www.ro-journal.com/content/4/1/4
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such as SBRT in stage I disease, we would accept compro-
mised coverage for PTV but not for IGTV. Therefore, IGTV
delineation accuracy is still crucial clinically.
As with other such comparative studies mentioned above,
inter or intra observer variability in the delineation of the
GTV was not considered. The uncertainties introduced as
a result of the above could however be thought to be dif-
ferent from those analyzed in this study, thereby requiring
a separate analysis that is beyond the scope of the current
report.
Conclusion
We found that the MIP-based and two-phase-based
approaches to IGTV delineation significantly underesti-
mated the IGTV in patients with stage I and stage III
NSCLC. Due to the limitations of each approach, a signif-
icant amount of the tumor volume could be missed in
individual patient so precautions should be taken when
these techniques are used to treat patients. We also found
that the IGTVMIP-Modified approach, which requires visual
verification of tumor coverage after each phase of the
breathing cycle, improved IGTV delineation in both cases.
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